Methotrexate

Generic Name: Methotrexate

Brand Names: Metoject, Nordimet, Otrexup, Rasuvo, Reditrex, Trexall, Xatmep, Jylamvo

Drug Type: Small Molecule

Chemical Formula: C_₂₀H_₂₂N_₈O_₅

CAS Number: 59-05-2

Unique Ingredient Identifier: YL5FZ2Y5U1

Background: Methotrexate is a folate derivative that inhibits several enzymes responsible for nucleotide synthesis. This inhibition leads to suppression of inflammation as well as prevention of cell division. Because of these effects, methotrexate is often used to treat inflammation caused by arthritis or to control cell division in neoplastic diseases such as breast ca...

Indication: Methotrexate oral solution is indicated for pediatric acute lymphoblastic leukemia and pediatric polyarticular juvenile idiopathic arthritis. Methotrexate injections for subcutaneous use are indicated for severe active rheumatoid arthritis, polyarticular juvenile idiopathic arthritis and severe, recalcitrant, disabling psoriasis.
...

Associated Conditions: Acute Lymphoblastic Leukemia (ALL), Acute Promyelocytic Leukemia, Bladder Cancer, Breast Cancer, Central Nervous System Lymphoma, Crohn's Disease (CD), Dermatomyositis (DM), Extrauterine Pregnancy, Gestational Trophoblastic Neoplasia, Graft-versus-host Disease (GVHD), Meningeal leukemia, Multiple Sclerosis, Mycosis Fungoides (MF), Non-Hodgkin's Lymphoma (NHL), Non-Hodgkin's Lymphoma, Relapsed, Osteosarcoma, Polyarticular Juvenile Idiopathic Arthritis, Polymyositis, Rheumatoid Arthritis, Soft Tissue Sarcoma, Squamous Cell Carcinoma of the Head and Neck (SCCHN), Systemic Lupus Erythematosus, Uveitis, Nonleukemic meningeal cancer, Refractory Non-Hodgkin's lymphoma, Refractory Takayasu arteritis, Severe Psoriasis

Associated Therapies: Medically induced abortion

Clinical Trials

Premedication to Reduce Amivantamab Associated Infusion Related Reactions

Phase 2

Active, not recruiting

Conditions: Carcinoma, Non-Small-Cell Lung

Interventions: Drug: Dexamethasone
Drug: Montelukast
Drug: Methotrexate
Drug: Amivantamab
Drug: Lazertinib

First Posted Date: 2022-12-23

Last Posted Date: 2024-12-06

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 73

Registration Number: NCT05663866

Locations: 🇫🇷
Hopital Europeen Georges-Pompidou, Paris, France
🇫🇷
CHU Rouen Hopital Charles Nicolle, Rouen, France
🇰🇷
Seoul National University Bundang Hospital, Gyeonggi-do, Korea, Republic of

and more 33 locations

Pediatric-inspired Regimen Combined With Venetoclax for Adolescent and Adult Patients With de Novo Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia

Phase 2

Recruiting

Conditions: Precursor Cell Lymphoblastic Leukemia-Lymphoma

Interventions: Drug: Vincristine
Drug: Daunorubicin
Drug: Cyclophosphamide
Drug: Pegaspargase
Drug: Prednisone
Drug: Cytarabine
Drug: 6-mercaptopurine
Drug: Dexamethasone
Drug: Methotrexate
Drug: Venetoclax

First Posted Date: 2022-12-21

Last Posted Date: 2023-03-03

Lead Sponsor: Institute of Hematology & Blood Diseases Hospital, China

Target Recruit Count: 100

Registration Number: NCT05660473

Locations: 🇨🇳
Institute of Hematology & Blood Diseases Hospital, Tianjin, China

Study of Pedi-cRIB: Mini-Hyper-CVD With Condensed Rituximab, Inotuzumab Ozogamicin and Blinatumomab (cRIB) for Relapsed Therapy for Pediatric With B-Cell Lineage Acute Lymphocytic Leukemia

Phase 2

Recruiting

Conditions: Leukemia

Interventions: Drug: Cyclophosphamide
Drug: Vincristine
Drug: Blinatumomab
Drug: Methotrexate
Drug: Cytarabine
Drug: Mercaptopurine
Drug: Prednisone
Drug: Pegfilgrastim
Drug: Inotuzumab ozogamicin
Drug: Rituximab
Drug: Dexamethasone

First Posted Date: 2022-12-09

Last Posted Date: 2024-07-19

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 27

Registration Number: NCT05645718

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

The Clinical Efficacy of Immunomodulators in RA Patients

Phase 4

Recruiting

Conditions: Arthritis, Rheumatoid

Interventions: Drug: Iguratimod
Drug: Adalimumab Injection
Drug: Methotrexate
Drug: Leflunomide
Drug: Hydroxychloroquine

First Posted Date: 2022-11-23

Last Posted Date: 2022-11-29

Lead Sponsor: Qilu Hospital of Shandong University

Target Recruit Count: 400

Registration Number: NCT05626348

Locations: 🇨🇳
Qilu Hospital, Jinan, Shandong, China

Methotrexate as Remission Maintenance Therapy After Remission-Induction With Tocilizumab and Glucocorticoids in Giant Cell Arteritis

Phase 2

Active, not recruiting

Conditions: Giant Cell Arteritis

Interventions: Drug: Methotrexate
Drug: Sodium chloride

First Posted Date: 2022-11-21

Last Posted Date: 2024-04-10

Lead Sponsor: University of Bonn

Target Recruit Count: 52

Registration Number: NCT05623592

Locations: 🇩🇪
Medical Clinic and Polyclinic III Internal medicine Oncology, Hematology University Hospital Bonn, Rheumatology and Clinical Immunology, Bonn, Germany

A Study Investigating Interactions Between BMS-986322 and Rosuvastatin, Metformin and Methotrexate in Healthy Participants

Phase 1

Completed

Conditions: Healthy Participants

Interventions: Drug: BMS-986322
Drug: Methotrexate
Drug: Rosuvastatin
Drug: Metformin
Dietary Supplement: Glucose
Drug: Leucovorin

First Posted Date: 2022-11-14

Last Posted Date: 2024-03-27

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 76

Registration Number: NCT05615012

Locations: 🇺🇸
Local Institution - 0001, Miami, Florida, United States

A Drug Interaction Study of LY3871801 in Healthy Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: LY3871801
Drug: Methotrexate
Drug: Warfarin
Drug: Dextromethorphan
Drug: Midazolam
Drug: Repaglinide

First Posted Date: 2022-11-02

Last Posted Date: 2023-04-18

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 39

Registration Number: NCT05602675

Locations: 🇺🇸
Covance Dallas, Dallas, Texas, United States

A Trial Comparing Unrelated Donor BMT with IST for Pediatric and Young Adult Patients with Severe Aplastic Anemia (TransIT, BMT CTN 2202)

Phase 3

Recruiting

Conditions: Severe Aplastic Anemia

Interventions: Drug: cyclosporine
Procedure: Matched Unrelated Donor Hematopoetic Stem Cell Transplant
Drug: horse anti-thymocyte globulin (ATG)
Procedure: Immunosuppressive Therapy (IST)
Drug: rabbit anti-thymocyte globulin (ATG)
Drug: Methotrexate
Drug: Fludarabine
Drug: Cyclophosphamide
Radiation: low-dose total body irradiation (TBI)

First Posted Date: 2022-10-31

Last Posted Date: 2024-11-08

Lead Sponsor: Boston Children's Hospital

Target Recruit Count: 234

Registration Number: NCT05600426

Locations: 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸
Phoenix Children's Hospital, Phoenix, Arizona, United States
🇺🇸
Arkansas, Little Rock, Arkansas, United States

and more 46 locations